Evolus (NASDAQ:EOLS) Rating Reiterated by Cantor Fitzgerald

Evolus (NASDAQ:EOLS)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, August 1st. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, August 1st.

Evolus Stock Performance

Shares of NASDAQ EOLS traded up $0.74 during midday trading on Monday, reaching $15.45. The company had a trading volume of 161,547 shares, compared to its average volume of 570,139. The stock has a market cap of $974.74 million, a P/E ratio of -14.65 and a beta of 1.30. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. Evolus has a 1 year low of $7.44 and a 1 year high of $16.29. The business’s 50-day simple moving average is $13.26 and its 200 day simple moving average is $12.98.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. On average, analysts forecast that Evolus will post -0.64 earnings per share for the current fiscal year.

Insider Activity at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently made changes to their positions in EOLS. Perceptive Advisors LLC increased its position in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after buying an additional 2,477,623 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Evolus by 5,627.2% in the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after buying an additional 930,566 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Evolus in the first quarter valued at approximately $11,628,000. Armistice Capital LLC purchased a new stake in shares of Evolus in the second quarter valued at approximately $3,906,000. Finally, Zimmer Partners LP purchased a new stake in shares of Evolus in the first quarter valued at approximately $4,200,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.